These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7570655)

  • 1. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling to understanding the mechanism of action of hazardous substances.
    Medinsky MA
    Toxicol Lett; 1995 Sep; 79(1-3):185-91. PubMed ID: 7570655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic and pharmacodynamic modeling in health risk assessment and characterization of hazardous substances.
    Leung HW; Paustenbach DJ
    Toxicol Lett; 1995 Sep; 79(1-3):55-65. PubMed ID: 7570674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of physiologically based pharmacokinetic modeling in human health risk assessment of hazardous substances.
    Clewell HJ
    Toxicol Lett; 1995 Sep; 79(1-3):207-17. PubMed ID: 7570658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA; Tessari JD
    Toxicol Lett; 1995 Sep; 79(1-3):193-200. PubMed ID: 7570656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment.
    Andersen ME
    Toxicol Lett; 1995 Sep; 79(1-3):35-44. PubMed ID: 7570672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Summary of panel discussion on the 'advantages/limitations/uncertainties in the use of physiologically based pharmacokinetic and pharmacodynamic models in hazard identification and risk assessment of toxic substances'.
    Frederick CB
    Toxicol Lett; 1995 Sep; 79(1-3):201-6. PubMed ID: 7570657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologically based pharmacokinetic/pharmacodynamic modeling of chemical mixtures and possible applications in risk assessment.
    el-Masri HA; Thomas RS; Benjamin SA; Yang RS
    Toxicology; 1995 Dec; 105(2-3):275-82. PubMed ID: 8571364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of mechanistic information in risk assessment for toxic chemicals.
    Becking GC
    Toxicol Lett; 1995 May; 77(1-3):15-24. PubMed ID: 7618129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapolating the future: research trends in modeling.
    Menzel DB
    Toxicol Lett; 1995 Sep; 79(1-3):299-303. PubMed ID: 7570670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moving from external exposure concentration to internal dose: duration extrapolation based on physiologically based pharmacokinetic derived estimates of internal dose.
    Simmons JE; Evans MV; Boyes WK
    J Toxicol Environ Health A; 2005 Jun 11-25; 68(11-12):927-50. PubMed ID: 16020185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment.
    Clewell HJ; Gentry PR; Gearhart JM
    J Toxicol Environ Health; 1997 Dec; 52(6):475-515. PubMed ID: 9397182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applications of computational toxicology methods at the Agency for Toxic Substances and Disease Registry.
    el-Masri HA; Mumtaz MM; Choudhary G; Cibulas W; De Rosa CT
    Int J Hyg Environ Health; 2002 Mar; 205(1-2):63-9. PubMed ID: 12018017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Toxicokinetic modeling and its applications in chemical risk assessment.
    Andersen ME
    Toxicol Lett; 2003 Feb; 138(1-2):9-27. PubMed ID: 12559690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK models in risk assessment--A focus on chloroprene.
    DeWoskin RS
    Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental and mathematical modeling methods for the investigation of toxicological interactions.
    El-Masri HA
    Toxicol Appl Pharmacol; 2007 Sep; 223(2):148-54. PubMed ID: 16996550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologically motivated quantitative models and the mixture toxicity problem.
    Conolly RB
    Toxicol Sci; 2001 Sep; 63(1):1-2. PubMed ID: 11509736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
    Marino DJ; Starr TB
    Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment.
    Kedderis GL; Lipscomb JC
    Toxicol Ind Health; 2001 Jun; 17(5-10):315-21. PubMed ID: 12539878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of physiologically based pharmacokinetic models for use in risk assessment.
    Chiu WA; Barton HA; DeWoskin RS; Schlosser P; Thompson CM; Sonawane B; Lipscomb JC; Krishnan K
    J Appl Toxicol; 2007; 27(3):218-37. PubMed ID: 17299829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Precision of estimates of an ADI (or TDI or PTWI).
    Speijers GJ
    Regul Toxicol Pharmacol; 1999 Oct; 30(2 Pt 2):S87-93. PubMed ID: 10597619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.